Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag vs Avatrombopag + rhTPO in Severe Aplastic Anemia
NCT06254287Phase 2Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of avatrombopag in aplastic anemia (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall Response Rate at 3 months. Status: unknown.
02
Drugs
avatrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06254287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254287.